These long-awaited results follow on the heels of similar announcements for nivolumab in melanoma and lung carcinoma. Based on these results, we are experiencing a sea change in the manner in which we practice oncology in general, and we will see significant changes in the practice algorithms used for RCC.
A couple of major questions arise:
- Can we identify individuals most likely to benefit from nivolumab?
- What can be done to convert nonresponders to responders?
The next few years will see continued development of immunotherapy as a treatment choice for patients with RCC.